Compare UNCY & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNCY | MSLE |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.3M | 146.9M |
| IPO Year | 2021 | N/A |
| Metric | UNCY | MSLE |
|---|---|---|
| Price | $6.63 | $6.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $38.00 | N/A |
| AVG Volume (30 Days) | ★ 489.9K | 109.7K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $675,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $407.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $5.50 |
| 52 Week High | $7.57 | $13.39 |
| Indicator | UNCY | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 37.82 |
| Support Level | $6.48 | $5.50 |
| Resistance Level | $7.12 | $7.52 |
| Average True Range (ATR) | 0.42 | 0.59 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 41.22 | 44.55 |
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.